Novo Nordisk CEO Open to Deals, Seeks Broadest Pipeline

In a recent interview, Novo Nordisk CEO Mike Rystar attributed the successful launch of the WGO pill to a combination of a strong product and dedicated personnel. He expressed confidence in the product's safety and efficacy, highlighting its superior tolerability and higher efficacy compared to competitors. The CEO also discussed the potential for the pill to expand the market for GLP-1s, particularly among men, and the rebranding of Rebelsis to the Ompic pill to reinvigorate sales. He acknowledged the importance of increasing the share of reimbursed channels while continuing to cater to cash-paying patients.